“…MD-based computational efforts evaluated the effect of omicron's mutations on ACE2 binding strength, [118,122,123] suggesting that YG339D, N440K, S477N, T478K, Q493K, N501Y increase the binding affinity, as also reported by Socher et al [124] S371L, S373P, S375F, K417N, G446S, E484A, G496S, Q498R, Y505H, on the other hand, decreased the binding affinity for ACE2, in agreement with a compensatory effect that moderates the binding strength of the enhancing mutations. [125] However, the reinforced network of hydrogen bonds, involving T500-D355, G502-K353, N487-Y83, as well as R493-D38, and A475-S19, paired with the electrostatic matching between R493-D38 and the loop shift caused by E484A and T478K mutation as suggested by Zhao et al, [126] suggesting an overall increase in the binding energy. These shifts seem to increase the complementarity between ACE2 and Omicron's RBD and could be the reason for the increased binding affinity, as also highlighted by Nie et al [127] The advent of the new VOC highlighted the necessity to follow multiple paths, for a broad-spectrum therapeutic approach, which should not only consider RBD as the target of main interest but should also consider more conserved viral proteins among the variants.…”